https://www.selleckchem.com/products/lc-2.html
82 (0.75-0.89); 0.00001] and PFS [0.81 (0.75-0.87); 0.00001], with OS benefits for anti-PD-L1 [0.73 (0.63-0.85); 0.0001] or anti-PD-1 [0.76 (0.63-0.93); 0.006] but not for anti-CTLA-4 [0.90 (0.80-1.01), = 0.07]. ORRs for ICI+CT or CT alone were comparable [odds ratio 1.12 (0.97-1.0; = 0.12], but responses at 12 months favored ICI+CT [4.16 (2.81-6.17), 0.00001]. Serious grade-3/4 AEs were more frequent with ICI+CT [odds ratio 1.18 (1.02-1.37); = 0.03]. Compared with CT, no ICI+CT benefit was found for ES
Like
Comment
Share
